Treatment options in hormone resistant prostate cancer.
作者信息
De Mulder P H M, Schalken J A, Sternberg C N
机构信息
Department of Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands.
出版信息
Ann Oncol. 2002;13 Suppl 4:95-102. doi: 10.1093/annonc/mdf645.
PMID:12401673
Abstract
摘要
相似文献
1
Treatment options in hormone resistant prostate cancer.
Ann Oncol. 2002;13 Suppl 4:95-102. doi: 10.1093/annonc/mdf645.
2
[Advanced prostatic carcinoma--which hormone therapy when?].[晚期前列腺癌——何时进行何种激素治疗？]
Urologe A. 1995 Sep;34(5):361-6.
3
Prostate cancer: management of advanced disease.前列腺癌：晚期疾病的管理
Ann Oncol. 2002;13 Suppl 4:89-94. doi: 10.1093/annonc/mdf644.
4
5
Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.研究改变了医生治疗转移性前列腺癌的方式：作者称，间歇性激素疗法不如持续性激素疗法有效。
Cancer. 2013 Sep 1;119(17):3103-4. doi: 10.1002/cncr.28314.
6
Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3].智慧之言：关于：盆腔放疗联合36个月与18个月雄激素阻断治疗高危前列腺癌：一项III期随机研究的结果[摘要3]
Eur Urol. 2013 Sep;64(3):513. doi: 10.1016/j.eururo.2013.06.028.
7
Progress in the treatment of advanced prostate cancer.晚期前列腺癌的治疗进展
Am Soc Clin Oncol Educ Book. 2014:117-31. doi: 10.14694/EdBook_AM.2014.34.117.
8
Choice of first-line treatment for metastatic prostate cancer.转移性前列腺癌一线治疗的选择。
Prescrire Int. 2013 Feb;22(135):51.
9
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.多西他赛联合雄激素剥夺疗法用于激素敏感性转移性前列腺癌患者：一项系统评价与荟萃分析
Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.
10
Cabazitaxel for castration-resistant prostate cancer.卡巴他赛用于去势抵抗性前列腺癌
Lancet. 2011 Jan 8;377(9760):121; author reply 122-3. doi: 10.1016/S0140-6736(11)60012-3.
Zotero 插件